Myasthenia gravis, respiratory function, and respiratory tract disease.
Comorbidity
Immunosuppressive treatment
Myasthenia gravis
Myasthenic crisis
Neonatal myasthenia
Respiratory disease
Ventilatory support
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jul 2023
Jul 2023
Historique:
received:
08
03
2023
accepted:
16
04
2023
revised:
14
04
2023
medline:
16
6
2023
pubmed:
27
4
2023
entrez:
26
4
2023
Statut:
ppublish
Résumé
Myasthenia gravis (MG) is characterized by muscle weakness caused by autoantibodies that bind to the postsynaptic membrane at the neuromuscular junction and impair acetylcholine receptor function. Weakness of respiratory muscles represents the most severe MG manifestation, and 10-15% of all patients experience an MG crisis with the need of mechanical ventilatory support at least once in their life. MG patients with respiratory muscle weakness need active immunosuppressive drug treatment long term, and they need regular specialist follow-up. Comorbidities affecting respiratory function need attention and optimal treatment. Respiratory tract infections can lead to MG exacerbations and precipitate an MG crisis. Intravenous immunoglobulin and plasma exchange are the core treatments for severe MG exacerbations. High-dose corticosteroids, complement inhibitors, and FcRn blockers represent fast-acting treatments that are effective in most MG patients. Neonatal myasthenia is a transient condition with muscle weakness in the newborn caused by mother's muscle antibodies. In rare cases, treatment of respiratory muscle weakness in the baby is required.
Identifiants
pubmed: 37101094
doi: 10.1007/s00415-023-11733-y
pii: 10.1007/s00415-023-11733-y
pmc: PMC10132430
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3329-3340Informations de copyright
© 2023. The Author(s).
Références
Alises SM, Castano A, Voth AH, Pizarro N, Caneiras C, Diaz-Lobato S (2018) Efficacy of mechanical insufflation-exhalation therapy in patiens with neuromuscular disease. Eur Respir J 52:2
Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ (2009) Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology 72:1548–1554
pubmed: 19414721
doi: 10.1212/WNL.0b013e3181a41211
Ambrogi V, Mineo TC (2017) Benefits of comprehensive rehabilitation therapy in thymectomy for myasthenia gravis a propensity score matching analysis. Am J Phys Med Rehabil 96:77–83
pubmed: 28099277
doi: 10.1097/PHM.0000000000000538
Andersen JB, Heldal AT, Engeland A, Gilhus NE (2014) Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries. Acta Neurol Scand 129:26–31
doi: 10.1111/ane.12233
Andersen JB, Owe JF, Engeland A, Gilhus NE (2014) Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study. Eur J Neurol 21:948–955
pubmed: 24712740
pmcid: 4238850
doi: 10.1111/ene.12439
Angstwurm K, Vidal A, Stetefeld H, Dohmen C, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, Neumann U, Lee DH, Gerner ST, Huttner HB, Thieme A, Dunkel J, Roth C, Schneider H, Schimmel E, Reichmann H, Fuhrer H, Berger B, Kleiter I, Schneider-Gold C, Alberty A, Zinke J, Schalke B, Steinbrecher A, Meisel A, Neumann B (2022) Early tracheostomy is associated with shorter ventilation time and duration of ICU stay in patients with myasthenic crisis–a multicenter analysis. J Intensive Care Med 37:32–40
pubmed: 33233998
doi: 10.1177/0885066620967646
Bach JF (2012) The etiology of autoimmune diseases: the case of myasthenia gravis. In: Wolfe GI, Meriggioli MN, Ciafaloni E, Ruff RL (eds) Myasthenia gravis and related disorders I. pp 33–39
Banner H, Niles KM, Ryu M, Sermer M, Bril V, Murphy KE (2022) Myasthenia gravis in pregnancy: systematic review and case series. Obstetr Med 15:108–117
doi: 10.1177/1753495X211041899
Barnett C, Bril V, Kapral M, Kulkarni A, Davis AM (2016) Development and validation of the Myasthenia Gravis Impairment Index. Neurology 87:879–886
pubmed: 27402891
pmcid: 5035154
doi: 10.1212/WNL.0000000000002971
Barohn RJ, McIntire D, Herbelin L, Wolfe GI, Nations S, Bryan WW (1998) Reliability testing of the quantitative myasthenia gravis score. In: Richman DP (ed) Myasthenia gravis and related diseases: disorders of the neuromuscular junction. pp 769–772
Bianchi DW, Vanmarter LJ (1994) An approach to ventilator-dependent neonates with arthrogryposis. Pediatrics 94:682–686
pubmed: 7936896
doi: 10.1542/peds.94.5.682
Blum S, Lee D, Gillis D, McEniery DF, Reddel S, McCombe P (2015) Clinical features and impact of myasthenia gravis disease in Australian patients. J Clin Neurosci 22:1164–1169
pubmed: 26021730
doi: 10.1016/j.jocn.2015.01.022
Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren J, Tallaksen CME (2015) An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts. Health Qual Life Outcomes 13:2
doi: 10.1186/s12955-015-0298-1
Breiner A, Bourque PR. Vaccination against COVID-19 does not lead to exacerbation in patients with myasthenia gravis. Muscle Nerve
Burns TM, Conaway MR, Cutter GR, Sanders DB, Grp MS (2008) Construction of an efficient evaluative instrument for myasthenia gravis: the mg composite. Muscle Nerve 38:1553–1562
pubmed: 19016543
doi: 10.1002/mus.21185
Burns TM, Sadjadi R, Utsugisawa K, Gwathmey KG, Joshi A, Jones S, Bril V, Barnett C, Guptill JT, Sanders DB, Hobson-Webb L, Juel VC, Massey J, Gable KL, Silvestri NJ, Wolfe G, Cutter G, Nagane Y, Murai H, Masuda M, Farrugia ME, Carmichael C, Birnbaum S, Hogrel JY, Nafissi S, Fatehi F, Ou CY, Liu WB, Conaway M (2016) International clinimetric evaluation of the MG-QOL15, resulting in slight revision and subsequent validation of the MG-QOL15R. Muscle Nerve 54:1015–1022
pubmed: 27220659
doi: 10.1002/mus.25198
Businaro P, Vaghi G, Marchioni E, Diamanti L, Arceri S, Bini P, Colombo E, Cosentino G, Alfonsi E, Costa A, Ravaglia S, Mallucci G, Ballante E, Franciotta D, Gastaldi M (2021) COVID-19 in patients with myasthenia gravis: epidemiology and disease course. Muscle Nerve 64:206–211
pubmed: 34031902
pmcid: 8242475
doi: 10.1002/mus.27324
Calik-Kutukcu E, Salci Y, Karanfil E, Fil-Balkan A, Bekircan-Kurt CE, Armutlu K (2019) Expiratory muscle strength as a predictor of functional exercise capacity in generalized myasthenia gravis. Neurosciences 24:95–100
pubmed: 31056540
pmcid: 8015462
doi: 10.17712/nsj.2019.2.20180024
Cavalcante P, Galbardi B, Franzi S, Marcuzzo S, Barzago C, Bonanno S, Camera G, Maggi L, Kapetis D, Andreetta F, Biasiucci A, Motta T, Giardina C, Antozzi C, Baggi F, Mantegazza R, Bernasconi P (2016) Increased expression of Toll-like receptors 7 and 9 in myasthenia gravis thymus characterized by active Epstein-Barr virus infection. Immunobiology 221:516–527
pubmed: 26723518
doi: 10.1016/j.imbio.2015.12.007
Cetin H, Beeson D, Vincent A, Webster R (2020) The structure, function, and physiology of the fetal and adult acetylcholine receptor in muscle. Front Mol Neurosci 13:25
doi: 10.3389/fnmol.2020.581097
Chang CC, Chen YK, Chiu HC, Yeh JH (2021) Changes in physical fitness and body composition associated with physical exercise in patients with myasthenia gravis: a longitudinal prospective study. J Clin Med 10:2
doi: 10.3390/jcm10174031
Cheng W, Sun T, Liu C, Zhou ZJ, Duan JX, Zhao YY, Yang M, Chen P (2021) A systematic review of myasthenia gravis complicated with myocarditis. Brain Behav 11:2
doi: 10.1002/brb3.2242
Culebras A (2005) Sleep disorders and neuromuscular disease. Semin Neurol 25:33–38
pubmed: 15798935
doi: 10.1055/s-2005-867071
De Leon AM, Aban I, McPherson T, Granit V, Benatar M, Cutter G, Lee IK Impact of the COVID-19 pandemic on patients with myasthenia gravis: a survey of the myasthenia gravis Foundation of America MG patient registry. Muscle Nerve
de Meel RHP, Tannemaat MR, Verschuuren J (2019) Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis. Neuromuscul Disord 29:664–670
pubmed: 31488385
doi: 10.1016/j.nmd.2019.07.006
Elsais A, Johansen B, Kerty E (2010) Airway limitation and exercise intolerance in well-regulated myasthenia gravis patients. Acta Neurol Scand 122:12–17
doi: 10.1111/j.1600-0404.2010.01369.x
Evoli A, Alboini PE, Damato V, Iorio R, Provenzano C, Bartoccioni E, Marino M (2018) Myasthenia gravis with antibodies to MuSK: an update. Ann N Y Acad Sci 1412:82–89
pubmed: 29266255
doi: 10.1111/nyas.13518
Evoli A, Padua L (2013) Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase. Autoimmun Rev 12:931–935
pubmed: 23535158
doi: 10.1016/j.autrev.2013.03.004
Farina A, Falso S, Cornacchini S, Spagni G, Monte G, Mariottini A, Massacesi L, Barilaro A, Evoli A, Damato V. Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: a multicenter experience. Eur J Neurol
Fregonezi GAD, Resqueti VR, Guell R, Pradas J, Casan P (2005) Effects of 8-week, interval-based inspiratory muscle training and breathing retraining in patients with generalized myasthenia gravis. Chest 128:1524–1530
pubmed: 16162753
doi: 10.1378/chest.128.3.1524
Freitag S, Hallebach S, Baumann I, Kalischewski P, Rassler B (2018) Effects of long-term respiratory muscle endurance training on respiratory and functional outcomes in patients with Myasthenia gravis. Respir Med 144:7–15
pubmed: 30366587
doi: 10.1016/j.rmed.2018.09.001
Gaissert H, Wilcox SR (2016) Diaphragmatic dysfunction after thoracic operations. Thorac Cardiovasc Surg 64:621–630
pubmed: 27888814
doi: 10.1055/s-0036-1595816
Gajdos P, Chevret S, Toyka KV (2012) Intravenous immunoglobulin for myasthenia gravis. Cochran Database Syst Rev 2:2
Gilhus N (2021) Physical training and exercise in myasthenia gravis. Neuromuscul Disord 31:169–173
pubmed: 33461846
doi: 10.1016/j.nmd.2020.12.004
Gilhus NE (2016) Myasthenia gravis. N Engl J Med 375:2570–2581
pubmed: 28029925
doi: 10.1056/NEJMra1602678
Gilhus NE (2020) Myasthenia gravis can have consequences for pregnancy and the developing child. Front Neurol 11:2
doi: 10.3389/fneur.2020.00554
Gilhus NE, Hong Y (2018) Maternal myasthenia gravis represents a risk for the child through autoantibody transfer, immunosuppressive therapy and genetic influence. Eur J Neurol 25:1402–1409
pubmed: 30133097
doi: 10.1111/ene.13788
Gilhus NE, Nacu A, Andersen JB, Owe JF (2015) Myasthenia gravis and risks for comorbidity. Eur J Neurol 22:17–23
pubmed: 25354676
doi: 10.1111/ene.12599
Gilhus NE, Romi F, Hong Y, Skeie GO (2018) Myasthenia gravis and infectious disease. J Neurol 265:1251–1258
pubmed: 29372387
doi: 10.1007/s00415-018-8751-9
Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM (2019) Myasthenia gravis. Nat Rev Dis Prim 5:30
pubmed: 31048702
doi: 10.1038/s41572-019-0079-y
Gilhus NE, Tzartos S, Evoli A, Palaces J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Prim 5:30
pubmed: 31048702
doi: 10.1038/s41572-019-0079-y
Gilhus NE, Verschuuren J, Hovland SIB, Simmonds H, Groot F, Palace J (2021) Myasthenia gravis: do not forget the patient perspective. Neuromuscul Disord 31:1287–1295
doi: 10.1016/j.nmd.2021.07.396
Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol 14:1023–1036
pubmed: 26376969
doi: 10.1016/S1474-4422(15)00145-3
Grob D, Brunner N, Namba T, Pagala M (2008) Lifetime course of myasthenia gravis. Muscle Nerve 37:141–149
pubmed: 18059039
doi: 10.1002/mus.20950
Gui MC, Luo X, Lin J, Li Y, Zhang M, Zhang XF, Yang MS, Wang W, Bu BT (2015) Long-term outcome of 424 childhood-onset myasthenia gravis patients. J Neurol 262:823–830
pubmed: 25588729
doi: 10.1007/s00415-015-7638-2
Haji K, Royse A, Green C, Botha J, Canty D, Royse C (2016) Interpreting diaphragmatic movement with bedside imaging, review article. J Crit Care 34:56–65
pubmed: 27288611
doi: 10.1016/j.jcrc.2016.03.006
Hamedani AG, Thibault D, Willis AW. Seasonal Variation in Neurologic Hospitalizations in the United States. Ann Neurol
Hannan LM, De Losa R, Romeo N, Muruganandan S. Diaphragm dysfunction: a comprehensive review from diagnosis to management. Intern Med J
Hansen JS, Danielsen DH, Somnier FE, Froslev T, Jakobsen J, Johnsen SP, Andersen H (2016) mortality in myasthenia gravis: a nationwide population-based follow-up study in Denmark. Muscle Nerve 53:73–77
pubmed: 25914186
doi: 10.1002/mus.24697
Harris L, Graham S, MacLachlan S, Exuzides A, Jacob S (2022) A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. Bmc Neurol 22:43
doi: 10.1186/s12883-022-02692-4
Heo SJ, Jun JS, Park D, Lee HW, Kim JS, Park JS (2019) Characteristics of obstructive sleep apnea in myasthenia gravis patients: a single center study. Neurol Sci 40:719–724
pubmed: 30648206
doi: 10.1007/s10072-019-3706-1
Hoff JM, Loane M, Gilhus NE, Rasmussen S, Daltveit AK (2011) Arthrogryposis multiplexa congenita: an epidemiologic study of nearly 9 million births in 24 EUROCAT registers. Eur J Obstetr Gynecol Reprod Biol 159:347–350
doi: 10.1016/j.ejogrb.2011.09.027
Holbro A, Jauch A, Lardinois D, Tzankov A, Dirnhofer S, Hess C (2012) High prevalence of infections and autoimmunity in patients with thymoma. Hum Immunol 73:287–290
pubmed: 22261388
doi: 10.1016/j.humimm.2011.12.022
Howard J, Vu T, Bril V, De Bleecker J, Verschuuren J, Mantegazza R, Meisel A, Peric S, de Haard H, Parys W, Guglietta A, Ulrichts P, Murai H (2020) ADAPT: a phase 3 study of fcrn antagonist, efgartigimod, in myasthenia gravis. Muscle Nerve 62:S76–S76
Howard JF, Utsugisawa K, Benatar M, al e, (2017) REGAIN: a randomised, double-blind, placebo-controlled, multi-centre study to evaluate the safety and efficacy of eculizumab in patients with anti-acetylcholine receptor positive refractory generalised myasthenia gravis. Lancet Neurol 3:4
Hsu CW, Lin HC, Tsai WC, Lai YR, Huang CC, Su YJ, Cheng BC, Su MC, Lin WC, Chang CL, Chang WN, Lin MC, Lu CH, Tsai NW (2020) Respiratory muscle training improves functional outcomes and reduces fatigue in patients with myasthenia gravis: a single-center hospital-based prospective study. Biomed Res Int 2020:2
doi: 10.1155/2020/2923907
Huang X, Liu WB, Men LN, Feng HY, Li Y, Luo CM, Qiu L (2013) Clinical features of myasthenia gravis in southern China: a retrospective review of 2,154 cases over 22 years. Neurol Sci 34:911–917
pubmed: 22806326
doi: 10.1007/s10072-012-1157-z
Inoue K, Tsugawa J, Fukae J, Fukuhara K, Kawano H, Fujioka S, Tsuboi Y (2020) Myasthenia gravis with anti-muscle-specific tyrosine kinase antibody during pregnancy and risk of neonatal myasthenia gravis: a case report and review of the literature. Case Rep Neurol 12:114–120
pubmed: 32308606
pmcid: 7154260
doi: 10.1159/000506189
Iwasa K, Yoshikawa H, Hamaguchi T, Sakai K, Shinohara-Noguchi M, Samuraki M, Takahashi K, Yanase D, Ono K, Ishida C, Yoshita M, Nakamura H, Yamada M (2018) Time-series analysis: variation of anti-acetylcholine receptor antibody titer in myasthenia gravis is related to incidence of Mycoplasma pneumoniae and influenza virus infections. Neurol Res 40:102–109
pubmed: 29173125
doi: 10.1080/01616412.2017.1407021
Jakubikova M, Tyblova M, Tesar A, Horakova M, Vlazna D, Rysankova I, Novakova I, Doleckova K, Dusek P, Pitha J, Vohanka S, Bednarik J (2021) Predictive factors for a severe course of COVID-19 infection in myasthenia gravis patients with an overall impact on myasthenic outcome status and survival. Eur J Neurol 28:3418–3425
pubmed: 34080271
pmcid: 8239548
doi: 10.1111/ene.14951
Kassardjian CD, Widdifield J, Paterson JM, Kopp A, Nagamuthu C, Barnett C, Tu K, Breiner A (2020) Serious infections in patients with myasthenia gravis: population-based cohort study. Eur J Neurol 27:702–708
pubmed: 31997519
doi: 10.1111/ene.14153
Katzberg HD, Vajsar J, Vezina K, Qashqari H, Selvadurai S, Chrestian N, Khayat A, Ryan CM, Narang I (2020) Respiratory dysfunction and sleep-disordered breathing in children with myasthenia gravis. J Child Neurol 35:600–606
pubmed: 32484036
doi: 10.1177/0883073820924213
Kim Y, Li XJ, Huang Y, Kim M, Shaibani A, Sheikh K, Zhang GQ, Nguyen TP (2022) COVID-19 outcomes in myasthenia gravis patients: analysis from electronic health records in the United States. Front Neurol 13:54
Kochhar PK, Schumacher RE, Sarkar S (2021) Transient neonatal myasthenia gravis: refining risk estimate for infants born to women with myasthenia gravis. J Perinatol 41:2279–2283
pubmed: 33597740
doi: 10.1038/s41372-021-00970-6
Konig N, Stetefeld HR, Dohmen C, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, Lee DH, Gerner ST, Huttner HB, Schneider H, Reichmann H, Fuhrer H, Berger B, Zinke J, Alberty A, Kleiter I, Schneider-Gold C, Roth C, Dunkel J, Steinbrecher A, Thieme A, Schlachetzki F, Linker RA, Angstwurm K, Meisel A, Neumann B (2021) MuSK-antibodies are associated with worse outcome in myasthenic crisis requiring mechanical ventilation. J Neurol 268:4824–4833
pubmed: 33970337
pmcid: 8563593
doi: 10.1007/s00415-021-10603-9
Kukulka K, Gummi RR, Govindarajan R (2020) A telephonic single breath count test for screening of exacerbations of myasthenia gravis: a pilot study. Muscle Nerve 62:258–261
pubmed: 32447763
doi: 10.1002/mus.26987
Kumai Y, Miyamoto T, Matsubara K, Samejima Y, Yamashita S, Ando Y, Orita Y (2019) Assessment of oropharyngeal swallowing dysfunction in myasthenia gravis patients presenting with difficulty in swallowing. Auris Nasus Larynx 46:390–396
pubmed: 30392978
doi: 10.1016/j.anl.2018.10.004
Laghi FA, Saad M, Shaikh H (2021) Ultrasound and non-ultrasound imaging techniques in the assessment of diaphragmatic dysfunction. Bmc Pulmon Med 21:32
Leis AA, Szatmary G, Ross MA, Stokic DS (2014) West nile virus infection and myasthenia gravis. Muscle Nerve 49:26–29
pubmed: 23559196
doi: 10.1002/mus.23869
Liu CC, Li T, Wang QY, Xu AD, Wu BQ (2021) Post-traumatic stress disorder symptoms after respiratory insufficiency in patients with myasthenia gravis. Psychol Health Med 26:221–227
pubmed: 32877257
doi: 10.1080/13548506.2020.1807577
Liu CJ, Chang YS, Teng CJ, Chen TJ, Ou SM, Tzeng CH, Wang SJ (2012) Risk of extrathymic cancer in patients with myasthenia gravis in Taiwan: a nationwide population-based study. Eur J Neurol 19:746–751
pubmed: 22221515
doi: 10.1111/j.1468-1331.2011.03621.x
Liu F, Wang Q, Chen XP (2019) Myasthenic crisis treated in a Chinese neurological intensive care unit: clinical features, mortality, outcomes, and predictors of survival. Bmc Neurol 19:22
doi: 10.1186/s12883-019-1384-5
Lupica A, Di Stefano V, Iacono S, Pignolo A, Quartana M, Gagliardo A, Fierro B, Brighina F (2022) Impact of COVID-19 in AChR myasthenia gravis and the safety of vaccines: data from an Italian cohort. Neurol Int 14:406–416
pubmed: 35645352
pmcid: 9149833
doi: 10.3390/neurolint14020033
Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1–11
doi: 10.1177/1756285617749134
Melamed RD, Khiabanian H, Rabadan R (2014) Data-driven discovery of seasonally linked diseases from an electronic health records system. Bmc Bioinform 15:22
doi: 10.1186/1471-2105-15-S6-S3
Misra UK, Kumar S, Singh VK, Dubey D, Kalita J (2020) Noninvasive ventilation in myasthenia gravis. Neurol India 68:648–651
pubmed: 32643679
doi: 10.4103/0028-3886.289001
Nacu A, Andersen JB, Lisnic V, Owe JF, Gilhus NE (2015) Complicating autoimmune diseases in myasthenia gravis: a review. Autoimmunity 48:362–368
pubmed: 25915571
pmcid: 4616023
doi: 10.3109/08916934.2015.1030614
Nelke C, Stascheit F, Eckert C, Pawlitzki M, Schroeter CB, Huntemann N, Mergenthaler P, Arat E, Ozturk M, Foell D, Schreiber S, Vielhaber S, Gassa A, Stetefeld H, Schroeter M, Berger B, Totzeck A, Hagenacker T, Meuth SG, Meisel A, Wiendl H, Ruck T (2022) Independent risk factors for myasthenic crisis and disease exacerbation in a retrospective cohort of myasthenia gravis patients. J Neuroinflam 19:2
doi: 10.1186/s12974-022-02448-4
Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Schonenberger S, Bosel J, Neumann U, Vidal A, Huttner HB, Gerner ST, Thieme A, Steinbrecher A, Dunkel J, Roth C, Schneider H, Schimmel E, Fuhrer H, Fahrendorf C, Alberty A, Zinke J, Meisel A, Dohmen C, Stetefeld HR (2020) Myasthenic crisis demanding mechanical ventilation: a multicenter analysis of 250 cases. Neurology 94:E299–E313
pubmed: 31801833
doi: 10.1212/WNL.0000000000008688
Ohlraun S, Hoffmann S, Klehmet J, Kohler S, Grittner U, Schneider A, Heuschmann PU, Meisel A (2015) Impact of myasthenia gravis on family planning: how do women with myasthenia gravis decide and why? Muscle Nerve 52:371–379
pubmed: 25557017
doi: 10.1002/mus.24556
Owe JF, Daltveit AK, Gilhus NE (2006) Causes of death among patients with myasthenia gravis in Norway between 1951 and 2001. J Neurol Neurosurg Psychiatry 77:203–207
pubmed: 16421123
pmcid: 2077560
doi: 10.1136/jnnp.2005.072355
Patone M, Handunnetthi L, Saatci D, Pan JF, Katikireddi SV, Razvi S, Hunt D, Mei XW, Dixon S, Zaccardi F, Khunti K, Watkinson P, Coupland CAC, Doidge J, Harrison DA, Ravanan R, Sheikh A, Robertson C, Hippisley-Cox J (2021) Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection (Oct, https://doi.org/10.1038/s41591-021-01556-7 , 2021). Nat Med 27:2249–2249
Peng SY, Tian YK, Meng LH, Fang RY, Chang WQ, Yang YJ, Li SH, Shen QQ, Ni JX, Zhu WZ (2022) The safety of COVID-19 vaccines in patients with myasthenia gravis: a scoping review. Front Immunol 13:2
doi: 10.3389/fimmu.2022.1103020
Pincheira AU, Alnajjar S, Katzberg H, Barnett C, Daniyal L, Rohan R, Bril V (2022) Retrospective study on the safety of COVID-19 vaccination in myasthenia gravis. Muscle Nerve 66:558–561
doi: 10.1002/mus.27657
Pisella LI, Fernandes S, Sole G, Stojkovic T, Tard C, Chanson JB, Bouhour F, Salort-Campana E, Beaudonnet G, Deberge L, Duval F, Grapperon AM, Masingue M, Nadaj-Pakleza A, Pereon Y, Audic F, Behin A, Friedman D, Magot A, Noury JB, Souvannanorath S, Wahbi K, Antoine JC, Bigaut K, Camdessanche JP, Cintas P, Debs R, Espil-Taris C, Kremer L, Kuntzer T, Laforet P, Laugel V, Mallaret M, Michaud M, Nollet S, Svahn J, Vicart S, Villar-Quiles RN, Desguerre I, Adams D, Segovia-Kueny S, Merret G, Hammouda E, Molon A, Attarian S (2021) A multicenter cross-sectional French study of the impact of COVID-19 on neuromuscular diseases. Orphanet J Rare Dis 16:2
doi: 10.1186/s13023-021-02090-y
Popperud TH, Boldingh MI, Rasmussen M, Kerty E (2017) Juvenile myasthenia gravis in Norway: Clinical characteristics, treatment, and long-term outcome in a nationwide population-based cohort. Eur J Paediatr Neurol 21:707–714
pubmed: 28457757
doi: 10.1016/j.ejpn.2017.04.003
Prelog M, Egli A, Zlamy M, Hirsch HH (2013) JC and BK polyomavirus-specific immunoglobulin G responses in patients thymectomized in early childhood. J Clin Virol 58:553–558
pubmed: 24055269
doi: 10.1016/j.jcv.2013.08.035
Ramos-Fransi A, Rojas-Garcia R, Segovia S, Marquez-Infante C, Pardo J, Coll-Canti J, Jerico I, Illa I, Myasthenia NMDESSG (2015) Myasthenia gravis: descriptive analysis of life-threatening events in a recent nationwide registry. Eur J Neurol 22:1056–1061
pubmed: 25847221
doi: 10.1111/ene.12703
Rassler B, Hallebach G, Kalischewski P, Baumann I, Schauer J, Spengler CM (2007) The effect of respiratory muscle endurance training in patients with myasthenia gravis. Neuromuscul Disord 17:385–391
pubmed: 17336068
doi: 10.1016/j.nmd.2007.01.001
Rodolico C, Bonanno C, Toscano A, Vita G (2020) MuSK-associated myasthenia gravis: clinical features and management. Front Neurol 11:2
doi: 10.3389/fneur.2020.00660
Romi F, Skeie GO, Gilhus NE, Aarli JA (2005) Striational antibodies in myasthenia gravis—reactivity and possible clinical significance. Arch Neurol 62:442–446
pubmed: 15767509
doi: 10.1001/archneur.62.3.442
Romi F, Aarli JA, Gilhus NE (2007) Myasthenia gravis patients with ryanodine receptor antibodies have distinctive clinical features. Eur J Neurol 14:617–620
pubmed: 17539937
doi: 10.1111/j.1468-1331.2007.01785.x
Roper J, Fleming ME, Long B, Koyfman A (2017) Myasthenia gravis and crisis: evaluation and management in the emergency department. J Emerg Med 53:843–853
pubmed: 28916122
doi: 10.1016/j.jemermed.2017.06.009
Ruiter AM, Verschuuren J, Tannemaat MR (2020) Fatigue in patients with myasthenia gravis. A systematic review of the literature. Neuromuscul Disord 30:631–639
pubmed: 32718868
doi: 10.1016/j.nmd.2020.06.010
Sansone G, Bonifati DM (2022) Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients. J Neurol 269:3965–3981
pubmed: 35503373
pmcid: 9062633
doi: 10.1007/s00415-022-11140-9
Schneider-Gold C, Gilhus NE (2021) Advances and challenges in the treatment of myasthenia gravis. Therap Adv Neurol Disord 14:2
Seok HY, Shin HY, Kim JK, Kim BJ, Oh J, Suh BC, Kim SY, Kang SY, Ahn SW, Bae JS, Kim BJ (2017) The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis. J Clin Neurol 13:325–330
pubmed: 29057629
pmcid: 5653619
doi: 10.3988/jcn.2017.13.4.325
Stascheit F, Grittner U, Hoffmann S, Mergenthaler P, Schroeter M, Ruck T, Pawlitzki M, Blaes F, Kaiser J, Schara U, Della-Marina A, Thieme A, Hagenacker T, Jacobi C, Berger B, Urban PP, Knop KC, Schalke B, Lee DH, Kalischewski P, Wiendl H, Meisel A (2023) Risk and course of COVID-19 in immunosuppressed patients with myasthenia gravis. J Neurol 270:1–12
pubmed: 36166068
doi: 10.1007/s00415-022-11389-0
Stetefeld HR, Schroeter M (2018) Myasthenic crisis. fortschritte der neurologie. Psychiatrie 86:301–307
Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R, Kroon FP, Rimmelzwaan GF, Verschuuren J (2019) A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine 37:919–925
pubmed: 30660402
doi: 10.1016/j.vaccine.2019.01.007
Suzuki S, Baba A, Kaida K, Utsugisawa K, Kita Y, Tsugawa J, Ogawa G, Nagane Y, Kuwana M, Suzuki N (2014) Cardiac involvements in myasthenia gravis associated with anti-Kv1.4 antibodies. Eur J Neurol 21:223–230
pubmed: 23829303
doi: 10.1111/ene.12234
Thomsen JLS, Andersen H (2020) Outcome measures in clinical trials of patients with myasthenia gravis. Front Neurol 11:596382
pubmed: 33424747
pmcid: 7793650
doi: 10.3389/fneur.2020.596382
Tomschik M, Hilger E, Rath J, Mayer EM, Fahrner M, Cetin H, Loscher WN, Zimprich F (2020) Subgroup stratification and outcome in recently diagnosed generalized myasthenia gravis. Neurology 95:E1426–E1436
pubmed: 32641537
doi: 10.1212/WNL.0000000000010209
Turk M, Weber I, Vogt-Ladner G, Schroder R, Winterholler M (2018) Diaphragmatic dysfunction as the presenting symptom in neuromuscular disorders: a retrospective longitudinal study of etiology and outcome in 30 German patients. Neuromuscul Disord 28:484–490
pubmed: 29748118
doi: 10.1016/j.nmd.2018.04.001
Vanoli F, Mantegazza R (2022) Antibody therapies in autoimmune neuromuscular junction disorders: approach to myasthenic crisis and chronic management. Neurotherapeutics 19:897–910
pubmed: 35165857
pmcid: 9294078
doi: 10.1007/s13311-022-01181-3
Walters J (2022) Weakness in the intensive care unit. Pract Neurol 22:358
doi: 10.1136/pn-2022-003422
Wang Y, Huan X, Jiao KX, Jiang QL, Goh LY, Shi JQ, Lv ZG, Xi JY, Song J, Yan C, Lin J, Zhu WH, Zhu XF, Zhou ZR, Xia R, Luo SS, Zhao CB (2022) Plasma exchange versus intravenous immunoglobulin in AChR subtype myasthenic crisis: a prospective cohort study. Clin Immunol 241:109058
pubmed: 35690385
doi: 10.1016/j.clim.2022.109058
Westerberg E, Molin CJ, Nees S, Widenfalk J, Punga AR (2018) The impact of physical exercise on neuromuscular function in Myasthenia gravis patients A single-subject design study. Medicine 97:e11510
pubmed: 30075515
pmcid: 6081147
doi: 10.1097/MD.0000000000011510
Westerberg E, Punga AR (2020) Mortality rates and causes of death in Swedish Myasthenia Gravis patients. Neuromuscul Disord 30:815–824
pubmed: 32962871
doi: 10.1016/j.nmd.2020.08.355
Wolfe G, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ (1999) Myasthenia gravis activities of daily living profile. Neurology 52:1487–1489
pubmed: 10227640
doi: 10.1212/WNL.52.7.1487
Yang XL, Niu L, Yang CW, Wang L, Liu JX, He GY (2019) Clinical features of laryngeal myasthenia gravis: a case series. Am J Otolaryngol 40:292–296
pubmed: 30497698
doi: 10.1016/j.amjoto.2018.11.002
Yingchoncharoen P, Charoenngam N, Ponvilawan B, Thongpiya J, Chaikijurajai T, Ungprasert P (2021) The association between asthma and risk of myasthenia gravis: a systematic review and meta-analysis. Lung 199:273–280
pubmed: 33987703
doi: 10.1007/s00408-021-00444-8
Zhou YF, Chen JL, Li ZB, Tan S, Yan C, Luo SS, Zhou L, Song J, Huan X, Wang Y, Zhao CB, Zeng WS, Xi JY (2022) Clinical features of myasthenia gravis with antibodies to MuSK based on age at onset: a multicenter retrospective study in China. Front Neurol 13:2
Zisimopoulou P, Brenner T, Trakas N, Tzartos SJ (2013) Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens. Autoimmun Rev 12:924–930
pubmed: 23537507
doi: 10.1016/j.autrev.2013.03.002
Zisimopoulou P, Evangelakou P, Tzartos J, Lazaridis K, Zouvelou V, Mantegazza R, Antozzi C, Andreetta F, Evoli A, Deymeer F, Saruhan-Direskeneli G, Durmus H, Brenner T, Vaknin A, Berrih-Aknin S, Cuvelier MF, Stojkovic T, DeBaets M, Losen M, Martinez-Martinez P, Kleopa KA, Zamba-Papanicolaou E, Kyriakides T, Kostera-Pruszczyk A, Szczudlik P, Szyluk B, Lavrnic D, Basta I, Peric S, Tallaksen C, Maniaol A, Tzartos SJ (2014) A comprehensive analysis of the epidemiology and clinical characteristics of anti-LRP4 in myasthenia gravis. J Autoimmun 52:139–145
pubmed: 24373505
doi: 10.1016/j.jaut.2013.12.004